Selvita

Selvita Current Liabilities

The Current Liabilities of Selvita (SLV.WA) as of Oct 21, 2026 is 118.61 M PLN. In the previous year, Current Liabilities was 379.99 M PLN — a change of -68.79% (lower).

Current Liabilities

118.61 MPLN

YoY

-68.79%

Last updated:

Current Liabilities of Selvita is 2025 118.61 M PLN. Current Liabilities of Selvita was 2024 379.99 M PLN. It decreases by -68.79% lower compared to the previous year.

The Selvita Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
15.61 M PLN
Jan 1, 2019
22.37 M PLN
Jan 1, 2020
52.16 M PLN
Jan 1, 2021
135.77 M PLN
Jan 1, 2022
182.00 M PLN
Jan 1, 2023
145.81 M PLN
Jan 1, 2024
379.99 M PLN
Jan 1, 2025
118.61 M PLN
The Selvita Current Liabilities history
YEARCurrent LiabilitiesYoY
118.61 MPLN-68.79%
379.99 MPLN+160.60%
145.81 MPLN-19.88%
182.00 MPLN+34.05%
135.77 MPLN+160.29%
52.16 MPLN+133.20%
22.37 MPLN+43.28%
15.61 MPLN+84.12%
8.48 MPLN-52.48%
17.84 MPLN+9.49%
16.29 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Selvita Stock analysis

What does Selvita do? Selvita SA generates revenue through multidisciplinary solutions for drug discovery, regulatory studies, and research and development. The company provides early-stage drug discovery support, including target validation and clinical candidate selection, alongside drug testing and bioanalytical services such as method development, stability studies, and quality control testing. Its clients include pharmaceutical companies and research institutions across Europe and the United States, which rely on Selvita's expertise for comprehensive project support throughout the drug development lifecycle. The firm's services span the entire drug discovery process, from initial target identification to preclinical research and clinical candidate selection. By offering end-to-end solutions, Selvita caters to clients seeking efficient and reliable support in complex research phases. Its collaborations with European and American research institutes and universities further strengthen its position in the biotech and pharmaceutical sectors. Selvita SA's business model focuses on delivering specialized scientific services tailored to the needs of clients in drug development. The company's offerings cover all critical stages of the drug discovery process, ensuring clients can advance their projects with minimal delays. This approach allows Selvita to maintain strong relationships with its key clients in the pharmaceutical and research communities. Selvita is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Selvita stock

Current Liabilities of Selvita is 118.61 M PLN in 2025.

Current Liabilities of Selvita changed from 379.99 M PLN to 118.61 M PLN, representing a -68.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Selvita since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Selvita historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Selvita

All Key Metrics — Selvita